Abstract
Objectives: Fear of opioid withdrawal syndrome (OWS) often dissuades opioid discontinuation. Lofexidine is an FDA-approved, alpha(2)-adrenergic recept......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
